Floatz logo

Methylphenidate

Apathy

Sunnybrook Health Sciences CentreSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Apathy cohort.

Asset / SponsorPhaseRating
Tvp-1012
University Hospital, Clermont-Ferrand
Phase 4BB
Rivastigmine
University Hospital, Lille
Phase 3B
Rotigotine
University Hospital, Grenoble
Phase 3B
Lumateperone
Louisiana State University Health Sciences Center Shreveport
Phase 3B
Modafinil
Brown University
Phase 3B

View all 13 →

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderDormant
BBB
Indicative ·
76 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
attention deficit-hyperactivity disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →